All‐cause mortality · people with pulmonary hypertension due to left‐heart disease
Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life · people with pulmonary hypertension due to left‐heart disease
1 finding from 1 review
PAP · people with pulmonary hypertension due to left‐heart disease
1 finding from 1 review
Cardiac index · people with pulmonary hypertension due to left‐heart disease
1 finding from 1 review
All‐cause mortality · pulmonary arterial hypertension
Group 1 Pulmonary arterial hypertension ‐ PDE5i leads to lower mortality compared with placebo (high certainty).
1 finding from 1 review
Improvement in WHO functional class · people with pulmonary hypertension due to lung disease
Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i may leads to higher improvement in WHO functional class compared with placebo (low certainty).
1 finding from 1 review
Six‐minute walk distance · people with pulmonary hypertension due to lung disease
1 finding from 1 review
All‐cause mortality · people with pulmonary hypertension due to lung disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with pulmonary hypertension due to lung disease
1 finding from 1 review
PAP · people with pulmonary hypertension due to lung disease
1 finding from 1 review
Cardiac index · people with pulmonary hypertension due to lung disease
1 finding from 1 review
PVR · people with pulmonary hypertension due to lung disease
1 finding from 1 review
RAP · people with pulmonary hypertension due to lung disease
1 finding from 1 review
Improvement in WHO functional class · people with pulmonary hypertension due to CTEPH
Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with placebo (low certainty).
1 finding from 1 review
Six‐minute walk distance · people with pulmonary hypertension due to CTEPH
2 findings from 1 review
QoL · pulmonary arterial hypertension
1 finding from 1 review
Mortality ‐ sildenafil versus placebo · people with pulmonary hypertension due to CTEPH
1 finding from 1 review
Mortality ‐ sildenafil versus bosentan · people with pulmonary hypertension due to CTEPH
Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i showed no clear difference in mortality ‐ sildenafil versus bosentan compared with placebo (low certainty).
1 finding from 1 review
Quality of life · people with pulmonary hypertension due to CTEPH
1 finding from 1 review
PAP · people with pulmonary hypertension due to CTEPH
2 findings from 1 review